British Biotech--on the Road to Recovery?

British Biotech, whose product setbacks and management missteps reduced its credibility to tatters and knocked the valuations of the UK biotech industry, is trying to rebuild itself, thanks to out-licensing deals with Schering-Plough and Serono, an in-licensing program designed to take advantage of its existing clinical infrastructure, and a shift towards anti-infectives.

It's more than two years since Elliot Goldstein, ex-SVP and director, worldwide strategic product development at SmithKline Beecham , became CEO of British Biotech PLC , whose credibility and share price had been reduced to tatters. A series of product setbacks, linked to the ousting of top executives, including research director Andy Millar, underlined management's failure to communicate realistically to investors. Once the bellwether of the young UK industry, British Biotech saw its market capitalization slide from a hyped and heady £2 billion down to £400 million in 1997, knocking the rest of the UK sector in the process.

But while Britain's biotech industry has long since picked itself up—policed by the BioIndustry Association's Code of Practice for communicating...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

test carousel

 
• By 

test carousel-In-Vivo

Slow Progress: A Decade Of Cell Therapy In Japan

 
• By 

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.

More from In Vivo

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By 

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By 

XXXXtesting